Global Proteomics | Next-Generation Proteomics | Large-Scale Proteomics

Powering precision medicine into reality

The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making.

OUR STORY

Transformative insights from discovery to clinic

Unbiased biological insights from tissue and biofluids

Novel drug target identification and validation

Custom panels for absolute protein quantification

Biognosys is the world leader in next-generation proteomics contract research services to support pharma and biotech research and clinical development.

OUR SERVICES

We offer a complete suite of software solutions for any mass spectrometry proteomics application in industry or academic life sciences research.

OUR SOFTWARE

Our kits and reagents for sample preparation, quantification and quality control empower researchers to apply cutting-edge proteomics in-house.

OUR KITS

 

Latest News & Stories

Resource - Launch Pages
Spectronaut: The Deepest Proteome Coverage Available

Spectronaut® 16 brings users the ability to identify and quantify more from their DIA data than ever[...]

READ MORE
News
Biognosys Pioneers AI-powered Proteomics to Provide the Deepest Proteome Coverage with Industry-leading Cost-efficiency

Unprecedented progress in Artificial Intelligence (AI)-enhanced data analysis with Spectronaut® expedites the performance and affordability of TrueDiscovery™ proteomics[...]

READ MORE
News
Biognosys Launches Spectronaut 16 and Presents Major Advances to its Proteomics Platforms at the ASMS 2022 Annual Conference

Highlights include the launch of Spectronaut® 16, which has undergone one of its most transformative upgrades to date, and innovations to Biognosys’ proprietary TrueTarget™[...]

READ MORE
News
Biognosys Expands Its Global Presence with a US Office in Biopharma Hub Cambridge, Massachusetts

The expansion is part of the company’s growth strategy for North America and will foster collaboration with life science companies and[...]

READ MORE
News
Biognosys Announces Appointment of Beat Lüthi, Ph.D., as independent Board Director

The appointment will support Biognosys’ transformation to a leading provider of protein insights for the development of new breakthrough[...]

READ MORE
News
Biognosys and NeoGenomics Expand Global Strategic Partnership Initiatives on Multiple Discovery Proteomics Solutions Supporting Biopharma R&D

Biognosys’ leading discovery proteomics services to add depth to NeoGenomics’ multiomics solutions for biopharma clinical trials and[...]

READ MORE
News
Biognosys Presenting Data on its TrueDiscovery™ and TrueTarget™ Proteomics Platforms at the AACR Annual Meeting 2022

Data from Biognosys and its collaborators demonstrate the technological advances and utility of their proteomics platforms in oncology R&D and clinical[...]

READ MORE
News
Biognosys Launches Expanded Suite of Proteomics Platforms to Support Drug Research and Development

The TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms provide an integrated suite of research services that reveal deep biological insights from early stage[...]

READ MORE
News
Biognosys Partners with Kymera Therapeutics in Precision Proteomics Biomarkers

Biognosys’ TrueSignature™ proteomics panels serve as pharmacodynamic readout for protein degradation in Kymera’s discovery and clinical trial[...]

READ MORE
News
Biognosys Launches Next-Generation Blood Biomarker Discovery Solution

The new and improved service will offer unprecedented depth, precision, and throughput, quantifying up to 3,000 proteins in plasma or[...]

READ MORE
News
Get Free Access to Our Software with Your Next PQ500™ Purchase

The limited-time offer includes a choice of 6 free months of SpectroDive™, our software for targeted proteomics, OR 3 free months of Spectronaut™, our DIA analysis[...]

READ MORE
News
Biognosys Reaches New Milestone in Tissue Proteomics

With a depth of up to 13,000 proteins, Biognosys’ proprietary HRM™ technology now enables near-complete quantification of tissue proteomes. [...]

READ MORE

Join Email List

    Select any of the below topic preferences: By submitting this form, you confirm that you agree to the processing of your personal data by Biognosys as described in the Privacy Notice.

    Join the Biognosys email list to receive news and exclusive content.

    Join Email List

      Select any of the below topic preferences: By submitting this form, you confirm that you agree to the processing of your personal data by Biognosys as described in the Privacy Notice.

      Helpdesk

      Access our knowledge base with relevant resources and guiding information.

      Access

      Contact

        Close banner

        Spectronaut® 16

        The Deepest Proteome
        Coverage Available

        New: Spectronaut® 16

        The Deepest Proteome Coverage Available

        learn more